Dr. Fu received his Ph.D. degree from Zhejiang University in 2017 and then worked as a postdoctoral fellow at St. Jude Children's Research Hospital in the United States from 2017 to 2022. He is a Pujiang talent in Shanghai. He joined Shanghai Immune Therapy Institute, Shanghai Jiao Tong University School of Medicine-Affiliated Renji Hospital in 2022.

Dr. Fu has a long-standing interest in studying the differentiation and function of CD4+ helper T cells. He has taken the fate decision of Tfh and Th17 cell differentiation as the core scientific question and has discovered that: (1) CDP–ethanolamine pathway as a selective metabolic and post-transcriptional checkpoint to program Tfh cell differentiation, and established the signaling function of de novo PE synthesis for underpinning the fate decisions of effector T cells. (2) ROS scavenger N-acetyl cysteine boosts Th17 cell differentiation in a MINK1-dependent manner and exacerbates the severity of EAE. In recent years, Dr. Fu made original works published in Nature and JEM as lead author and did cooperative studies published in Nature, Cell, PNAS, and Osteoarthritis Cartilage as co-author.

Currently, Dr. Fu's lab focusing on T cell differentiation, metabolism, and tumor immunity, aiming to apply multiple systems biology tools, such as CRISPR screening, single-cell sequencing, and spatial transcriptomics, etc., to combine with disease modeling to reveal the mechanism of tumor immunity, and the mechanism of T cell immunomodulation, which will provide new strategies to help the human body fight against related immune system diseases.